Barry Katzen, Miami, USA, announced the establishment of a new society, the Critical Limb Ischaemia (CLI) Global Society, whose mission is to improve quality of life by preventing amputations and death due to the condition.
Scott Trerotola presented the first release of eight-month data from the Lutonix AV IDE trial at the Leipzig Interventional Course (LINC; 24–27 January, Leipzig, Germany) and showed that drug-coated balloons (Lutonix 035 AV from Bard) are linked with a significantly higher target lesion patency and far fewer reinterventions to maintain this opening in a wide variety of failing arteriovenous fistulas than standard angioplasty.
Penumbra has announced the presentation of the results of the ASTER trial, the first independent, prospective, randomised trial comparing the use of Penumbra’s aspiration system to stent retriever, in the opening plenary session at the International Stroke Conference in Houston, Texas.
Cook Medical has rounded out the Universa line with the introduction of two new sets for percutaneous urinary drainage.
BTG has announced that US FDA 510(k) clearance has been granted to the Ekos control unit 4.0.
Mentice has announced the release of the world’s first simulation training software module for prostatic artery embolization. The software, created from real patients’ data, will allow interventional radiologists to train for the procedure.
Surefire, the developer of site-specific delivery devices for the interventional oncology market, has announced the first closing of a US$12.8 M Series D financing round.
Nobilis Health has closed its previously announced acquisition of Hamilton Vein Center.
The pivotal VeClose trial is investigating the performance of the VenaSeal cyanoacrylate-based adhesive (Medtronic) for vein closure. At LINC 2017, Vascular News caught up with Raghu Kolluri (OhioHealth Vascular Institute, Columbus, USA) who explained his experience with the system thus far and why he is excited about the trial’s “excellent” 24-month outcomes.
Having received CE mark approval in July and Health Canada approval in August of last year, FlowAid Medical Technologies has now received US Food and Drug Administration (FDA) clearance for its FA100 SCCD (Sequential Continuous Contraction Device) for the following indications: increase of local blood circulation, immediate post-surgical stimulation of calf muscles to prevent venous thrombosis, prevention or retardation of disuse atrophy and oedema reduction. FlowAid says that the FA100 SCCD is the first device of its kind cleared by the FDA for the indication of oedema reduction.
Two-year outcomes of the VeClose pivotal trial have been reported, showing a 94.3% closure rate and “continued non-inferiority results to radiofrequency ablation” when using the VenaSeal cyanoacrylate embolic adhesive closure system (Medtronic). The data were presented by Raghu Kolluri, from OhioHealth Vascular Institute Columbus, USA, at the 2016 VEITHsymposium (15–19 November, New York, USA).
A Dutch study of greater saphenous vein insufficiency patients has found that mechanochemical ablation (MOCA; ClariVein, Vascular Insights) is an effective and safe treatment with low postoperative pain and fast recovery.
Fresh data from a Turkish CAPE (cyanoacrylate adhesive perforator embolisation) trial indicate that the method is “as effective as endovenous thermoablative techniques, without the risks of potential inadvertent thermal lesions” for treating incompetent perforating veins. The presentation was given by Kursat Bozkurt, Istanbul University, Istanbul, Turkey, at the 2016 VEITHsymposium (15–19 November, New York, USA).
TVA Medical has provided clinical updates involving its everlinQ endoAVF system at the 2017 Leipzig Interventional Course (LINC; 24-17 January, Leipzig, Germany).
The All Party Parliamentary Group on Vascular Disease has released its latest report on patient access to technologies for the diagnosis and treatment of peripheral arterial disease.
Cookies Sociales
Son esos botones que permiten compartir el contenido del sitio web en sus redes sociales (Facebook, Twitter y Linkedin, previo tu consentimiento y login) a través de sistemas totalmente gestionados por dichas redes sociales, así como los recursos (pej. videos) y material que se encuentra en nuestra web, y que de igual manera se presta y gestiona completamente por un tercero.
Si no acepta estas cookies, no podrá compartir nuestro contenido a través de los botones, y en su caso, no podrás visualizar el contenido de terceros que hayamos incrustado en el sitio.
No las utilizamos